RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients.
Medical Services Advisory Committee
Record ID 32015000451
English
Authors' objectives:
The RAS mutation test is a combination of genetic tests, conducted on a biopsy sample, to tell whether a tumour carries a RAS mutation(s). KRAS and NRAS are highly related members of the RAS oncogene family which have an important role in the development and continued growth of colorectal cancer. The KRAS gene is found to be mutated, or changed, in about 40% of people with colorectal cancer. The NRAS gene is found to be mutated in an additional 10-15% of patients. The other ~50% of people have a non-mutated (sometimes called "wild type") RAS genes.
Widespread colorectal cancer is treated with chemotherapy and patients may receive several sequential courses of different types of chemotherapy as the disease progresses. For patients with widespread disease the prognosis is poor with only 10% of patients still alive 5 years after diagnosis.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1363-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Antineoplastic Agents
- Antibodies, Monoclonal
- ras Proteins
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.